MJN110 is an orally potent and specific monoacylglycerol lipase (MAGL) inhibitor (antagonist) with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively. MJN110 can produce protective effects of opioid-active molecules and has strong anti-hyperalgesic activity.

Physicochemical Properties

Molecular Formula	C22H21CL2N3O4
Molecular Weight	462.327
Exact Mass	461.091
CAS #	1438416-21-7
PubChem CID	71722059
Appearance	White to off-white solid powder
Density	1.47±0.1 g/cm3
Boiling Point	561.5±60.0 °C
LogP	3.714
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	5
Heavy Atom Count	31
Complexity	632
Defined Atom Stereocenter Count	0
InChi Key	BEADRWVIFHOSGN-UHFFFAOYSA-N
InChi Code	InChI=1S/C22H21Cl2N3O4/c23-17-5-1-15(2-6-17)21(16-3-7-18(24)8-4-16)25-11-13-26(14-12-25)22(30)31-27-19(28)9-10-20(27)29/h1-8,21H,9-14H2
Chemical Name	(2,5-dioxopyrrolidin-1-yl) 4-[bis(4-chlorophenyl)methyl]piperazine-1-carboxylate
Synonyms	MJN110; MJN 110; MJN-110
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	The main target of serine hydrolase, hMAGL, is MJN110 (0.01-1000 nM; 4 hours); its IC50 is about 1 nM, and its selectivity window is 10- and 100-fold greater than that of ABHD6 and LYPLA1/2, respectively [2].
ln Vivo	In a dose-dependent manner, MJN110 (ip; 0.0818 mg/kg; twice daily for 5.5 days) reverses the effects of chronic constriction injury (CCI) on mechanical allodynia and thermal hyperalgesia. 0.430 (0.233-0.793) mg/kg is the comparable ED50 value (95% confidence limit)[1].
Cell Assay	Western blot analysis[2] Cell Types: Human PC3 cells Tested Concentrations: 0.01, 0.1, 1, 10, 100, 1000 nM Incubation Duration: 4 hrs (hours) Experimental Results: HMAGL acts as a major serine hydrolase target with an IC50 of approximately 1 nM.
Animal Protocol	Animal/Disease Models: Male C57BL/6J mice, body weight range 18 to 35 g[1] Doses: 0.0818 mg/kg Route of Administration: intraperitoneal (ip) injection; twice (two times) daily for 5.5 days Experimental Results: Reversal of CCI-induced disease in a dose-dependent manner of mechanical allodynia and thermal hyperalgesia.
References	[1]. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. J Pharmacol Exp Ther. 2016 Apr;357(1):145-56. [2]. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci. 2013 Sep 18;4(9):1322-32.
Additional Infomation	MJN110 is a diarylmethane.

Solubility Data

Solubility (In Vitro)

DMSO : ~250 mg/mL (~540.74 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.1630 mL	10.8148 mL	21.6296 mL
	5 mM	0.4326 mL	2.1630 mL	4.3259 mL
	10 mM	0.2163 mL	1.0815 mL	2.1630 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.